PIM
VRTX icon

Plato Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Plato Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3M Buy
6,083
+148
+2% +$65.6K 0.17% 129
2026
Q1 		$2.65M Hold
5,935
– – 0.18% 130
2025
Q4 		$2.7M Sell
5,935
-91
-2% -$39.2K 0.18% 123
2025
Q3 		$2.34M Buy
6,026
+197
+3% +$82.3K 0.16% 135
2025
Q2 		$2.59M Buy
5,829
+4
+0.1% +$1.84K 0.19% 113
2025
Q1 		$2.85M Sell
5,825
-820
-12% -$382K 0.24% 97
2024
Q4 		$2.69M Hold
6,645
– – 0.2% 114
2024
Q3 		$3.09M Hold
6,645
– – 0.25% 100
2024
Q2 		$3.11M Buy
6,645
+505
+8% +$219K 0.29% 82
2024
Q1 		$2.57M Buy
6,140
+5,350
+677% +$2.26M 0.27% 99
2023
Q4 		$321K Buy
+790
New +$292K 0.39% 61

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Plato Investment Management's VRTX Position: Q2 2026 in Review

Plato Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 2.5% in Q2 2026, buying an estimated $65.6K and bringing the position to 6,083 shares worth $3M. The position accounts for 0.17% of the portfolio, ranked #129.

Plato Investment Management first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $3.11M in Q2 2024. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Plato Investment Management held 6,083 shares of Vertex Pharmaceuticals worth $3M as of Q2 2026.
  • Plato Investment Management bought 148 Vertex Pharmaceuticals shares in Q2 2026, an estimated $65.6K.
  • Vertex Pharmaceuticals made up 0.17% of Plato Investment Management's portfolio in Q2 2026, its #129 holding.
  • Plato Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Plato Investment Management's Vertex Pharmaceuticals position peaked at $3.11M in Q2 2024.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Plato Investment Management's 13F filing for Q2 2026, filed 7 Aug 2026.